Low plasma concentrations of docosahexaenoic acid (DHA) are reported in unsupplemented cystic fibrosis (CF) patients. Forty-one CF patients aged from 6 to 12 years were randomized to receive high-dose DHA (100 mg/kg/day in the first month and 1g per day thereafter through a 12-month supplementation) or placebo (germ oil). Primary outcome was percentage change in plasma AA:DHA ratio. Secondary outcomes were changes in the number of pulmonary exacerbations compared to previous year, lung function, BMI, skinfold thicknesses, and body composition assessed by DXA and in serum concentrations of C-reactive protein, cytokines and vitamin (α-tocopherol and retinol). Compared to the control group plasma AA:DHA ratio decreased in the intervention group after 6 months (median percentage changes: -73% in the intervention group vs. -10% in the control group, P=0.001). No differences were detected between groups for secondary outcomes. Despite a decrease of the AA/DHA ratio, DHA supplementation for one year did not induce any significant biochemical and clinical improvement in CF patients.

A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis / G. Alicandro, N. Faelli, R. Gagliardini, B. Santini, G. Magazzù, A. Biffi, P. Risé, C.L. Galli, A..S. Tirelli, S. Loi, L. Valmarana, N. Cirilli, T. Palmas, G. Vieni, M..L. Bianchi, C.V. Agostoni, C. Colombo. - In: PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS. - ISSN 0952-3278. - 88:2(2013 Feb), pp. 163-169.

A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis

G. Alicandro;P. Risé;C.L. Galli;L. Valmarana;C.V. Agostoni;C. Colombo
2013-02

Abstract

Low plasma concentrations of docosahexaenoic acid (DHA) are reported in unsupplemented cystic fibrosis (CF) patients. Forty-one CF patients aged from 6 to 12 years were randomized to receive high-dose DHA (100 mg/kg/day in the first month and 1g per day thereafter through a 12-month supplementation) or placebo (germ oil). Primary outcome was percentage change in plasma AA:DHA ratio. Secondary outcomes were changes in the number of pulmonary exacerbations compared to previous year, lung function, BMI, skinfold thicknesses, and body composition assessed by DXA and in serum concentrations of C-reactive protein, cytokines and vitamin (α-tocopherol and retinol). Compared to the control group plasma AA:DHA ratio decreased in the intervention group after 6 months (median percentage changes: -73% in the intervention group vs. -10% in the control group, P=0.001). No differences were detected between groups for secondary outcomes. Despite a decrease of the AA/DHA ratio, DHA supplementation for one year did not induce any significant biochemical and clinical improvement in CF patients.
Cystic fibrosis; Docosahexaenoic acid; Plasma fatty acids; Randomised clinical trial; Supplementation
Settore MED/38 - Pediatria Generale e Specialistica
21-dic-2012
Article (author)
File in questo prodotto:
File Dimensione Formato  
Prostaglandins Leukot Essent Fatty Acids 2013, p. 163 - Agostoni.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 176.66 kB
Formato Adobe PDF
176.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/219094
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 22
social impact